Navigation Links
Pharmasset Reports Fiscal Third Quarter 2009 Financial Results
Date:8/10/2009

PRINCETON, N.J., Aug. 10 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the fiscal quarter ended June 30, 2009.

Financial Results

Revenues were $10.5 million during the quarter ended June 30, 2009 compared to $0.5 million for the quarter ended June 30, 2008 and reflect the receipt of a $10.0 million milestone payment from Roche, following the initiation of the phase 2b study with RG7128, and the amortization of up-front and subsequent collaborative and license payments received from Roche.

Net cash used in operating activities was $5.8 million for the quarter ended June 30, 2009 as compared to $12.7 million for the quarter ended June 30, 2008. Pharmasset held $72.7 million in cash and cash equivalents at the end of the fiscal third quarter.

Total operating expenses for the quarter ended June 30, 2009 were $16.7 million as compared to $15.0 million for the same period in 2008. The increase in operating expenses for the quarter ended June 30, 2009 was primarily the result of an increase in clinical development expenses for PSI-7851, our second generation hepatitis C virus (HCV) product candidate, and preclinical development expenses for our purine series of compounds. Partially offsetting these increases were reduced expenses for our clevudine Phase 3 registration studies that were terminated during the quarter.

Pharmasset reported a net loss of $6.9 million, or $0.25 per share, for the quarter ended June 30, 2009, as compared to a net loss of $15.0 million, or $0.69 per share, for the quarter ended June 30, 2008.


'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Pharmasset Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development
2. Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
3. Pharmasset to Present at Deutsche Bank Healthcare Conference
4. Pharmasset to Present at Two Upcoming Investor Conferences
5. Pharmasset to Present at Two Upcoming Investor Conferences
6. Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference
7. Pharmasset to Webcast an Investor Event from the AASLD Meeting
8. Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
9. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
10. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
11. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 Just as fitness and ... consider their own financial and marketing strength to be ... campaigns to the next level by using the most ... IVR, Voice Broadcast, Call Tracking and SMS texting ... rate, text messages are quickly become integral in marketing ...
(Date:7/24/2014)... July 24, 2014 CarePoint Health ... in hematology and oncology, Dr. Hitendra Upadhyaya, has ... system welcomes Dr. Upadhyaya to the community. Hundreds ... Health Medical Group, a comprehensive network of top ... wide range of specialties. This latest acquisition represents ...
(Date:7/24/2014)... found a way to delay or even prevent Alzheimer,s ... the anti-aging protein Klotho can prevent neuron death in ... These findings currently appear in the Journal of ... most frequent age-related dementia affecting 5.4 million Americans including ... more than 40 percent of people over the age ...
(Date:7/24/2014)... News) -- Drinking caffeine may worsen the hot flashes ... as they go through menopause, new survey data suggests. ... that limiting caffeine intake may be useful for those ... sweats," said researcher Dr. Stephanie Faubion, director of the ... Minn. But caffeine -- a stimulant found in ...
(Date:7/24/2014)... Hospital and the University of Tennessee Health Science Center ... drug shown to safely reduce the viral load and ... respiratory syncytial virus (RSV). RSV is the most common ... in the United States and worldwide. , The ... John DeVincenzo, MD. DeVincenzo,s Le Bonheur lab has been ...
Breaking Medicine News(10 mins):Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 2Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 3Health News:Dr. Upadhyaya Joins CarePoint Health Medical Group 2Health News:BU researchers discover that Klotho is neuroprotective against Alzheimer's disease 2Health News:Is Coffee Aggravating Your Hot Flashes? 2Health News:RSV research breakthrough to help infected children 2
... ... - Gross margin expanded to 32.4 percent from ... Health management segment revenue grew 25 percent, - Net earnings: ... Nov. 3 Health Fitness,Corporation (NYSE Alternext US: FIT), a leading provider ...
... Held on Thursday November 6 at 8:30,a.m., NEW ... Board: VION) today announced financial,results for the three-month and ... a net loss of $6.8 million, or $0.92 per ... to a net loss,of $9.0 million, or $1.33 per ...
... neck, government study finds , , MONDAY, Nov. 3 (HealthDay ... with human papillomavirus (HPV) occurred in 38 states and ... officials reported Monday. , HPV is a group of ... than 30 of which can be sexually transmitted. Most ...
... A recent study conducted by researchers at Georgia ... demonstrate that administration of preemptive morphine prior to a ... of pain in adult rodents. These studies have ... administered to neonates prior to surgery. Infant rodents that ...
... Center at the University of California, San Diego (UCSD) ... at revving up the immune system to combat a ... therapy is being offered to patients with chronic lymphocytic ... resistant to initial treatment or harbors a particular chromosomal ...
... Revenue for the third quarter 2008 increases 32% to $16.0 million. - Heart ... surgical ablation products revenue grows 21.7%. ... Company raises lower end of its 2008 revenue guidance to $65 - $66 ... ...
Cached Medicine News:Health News:HealthFitness Announces 2008 Third Quarter Results 2Health News:HealthFitness Announces 2008 Third Quarter Results 3Health News:HealthFitness Announces 2008 Third Quarter Results 4Health News:HealthFitness Announces 2008 Third Quarter Results 5Health News:HealthFitness Announces 2008 Third Quarter Results 6Health News:HealthFitness Announces 2008 Third Quarter Results 7Health News:HealthFitness Announces 2008 Third Quarter Results 8Health News:HealthFitness Announces 2008 Third Quarter Results 9Health News:HealthFitness Announces 2008 Third Quarter Results 10Health News:Vion Reports 2008 Third Quarter and Nine-Month Results 2Health News:Vion Reports 2008 Third Quarter and Nine-Month Results 3Health News:Vion Reports 2008 Third Quarter and Nine-Month Results 4Health News:Vion Reports 2008 Third Quarter and Nine-Month Results 5Health News:U.S. Reported 25,000 Cases of HPV-Related Cancers Annually 2Health News:GSU study first to confirm long-term benefits of morphine treatment in infants 2Health News:Moores UCSD Cancer Center studying novel leukemia vaccine for high-risk patients 2Health News:ATS Medical Announces Third Quarter Results 2Health News:ATS Medical Announces Third Quarter Results 3Health News:ATS Medical Announces Third Quarter Results 4Health News:ATS Medical Announces Third Quarter Results 5Health News:ATS Medical Announces Third Quarter Results 6Health News:ATS Medical Announces Third Quarter Results 7Health News:ATS Medical Announces Third Quarter Results 8
(Date:7/24/2014)...  Restore Health, a leading personalized medicine company ... it is now offering pharmacogenetics testing that provides ... upon their particular genetic makeup. Comprehensive medication management ... a patient,s genetics and their entire drug regimen.  ... this new service to healthcare providers and their ...
(Date:7/24/2014)... -- Uroplasty, Inc. (NASDAQ: UPI ), a medical ... proprietary products to treat voiding dysfunctions, today reported ... ended June 30, 2014.  Global revenue for ... 19% to $4.1 million, as compared to $3.4 ... year.  Total revenue for the fiscal first quarter ...
(Date:7/24/2014)... July 24, 2014  IRIDEX Corporation (NASDAQ: ... second quarter 2014 financial results after the market closes ... with the release, the Company will host a conference ... Eastern Time on Thursday, July 31, 2014 ... other business developments. Interested parties may access ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11
... , REDWOOD CITY, Calif., Dec. 24 Maxygen, Inc. ... development of improved versions of protein drugs, today announced the ... expired at 5:00 p.m., New York City time, on December ... by the depositary for the tender offer, Maxygen expects to ...
... , , GREENSBORO, N.C., Dec. 23 ... four users who allege kidney damage due to the use ... in preparation for a colonoscopy. (Holshouser et al v. ... are against two Morrisville, N.C., pharmaceutical companies, Salix Pharmaceuticals, Ltd., ...
Cached Medicine Technology:Maxygen, Inc. Announces Preliminary Results of Dutch Auction Tender Offer 2Suits Commenced Against Maker of Prescription Cleansing Drug 2
... Designed To Hold & Support A Dropping Lens ... & Phacoemulsification To ,Continue. Can ... Of A Cyclodialysis Spatula To Reach Into ... Salvage Lens Fragments With One Instrument. ...
... Are Available In Two Models: One Is Direct ... Jaws Close. The Other Model Is Reverse ... Compressed The Jaws Open., ,The Forceps Are 22g, ... Through A 1.1mm Incision. These Forceps Allow The ...
... Designed To Dial An Exact Extension Of ... Maximum Visibility, With Titanium Handle & Spring. ... In Tissue, And Can Also Be Dialed ... Autoclaveable, Made In The USA, Handle Guaranteed ...
... The 0.1mm Pierce Tip Opening ... Flap, Without The Need For A Separate Cystotome. ... Grasping Positions Without Elevating The Incision.,The Distal Jaws ... Blades Help To Prevent Inadvertent Pick Up Of ...
Medicine Products: